Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity

Ewelina Kluza; Sin Yuin Yeo; Sophie Schmid; Daisy W. J. Van der Schaft; Renate W. Boekhoven; Raymond M. Schiffelers; Gert Storm; Gustav J. Strijkers; Klaas Nicolay

doi:10.1016/j.jconrel.2010.11.031

Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity

Ewelina Kluza^*, Sin Yuin Yeo, Sophie Schmid, Daisy W. J. Van der Schaft, Renate W. Boekhoven, Raymond M. Schiffelers, Gert Storm, Gustav J. Strijkers, Klaas Nicolay

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Tumor-associated inflammation has been recognized as an important tumor growth propagator and, therefore, represents an attractive target for anti-cancer therapy. In the current study, inspired by recent findings on the anti-tumor activity of liposomal glucocorticoids, we introduce paramagnetic and fluorescent liposomes, encapsulating prednisolone phosphate (PLP), to evaluate the local delivery of liposomal glucocorticoids to the tumor and its importance for the therapeutic response. The new multifunctional liposomes (Gd-PLP-L) (120nm diameter, 5.8mg PLP/60?mol lipid, bioexponential blood-clearance kinetics (T(1/2?)=2.4?0.5h, T(1/2?)=42.0?12.4h), drug leakage of 15%/72h (in vitro)), containing 25mol% Gd-DTPA-lipid and 0.1mol% of rhodamine-lipid, were tested in B16F10 melanoma subcutaneously inoculated in C57BL/6 mice, and compared to the original PLP formulation (PLP-L). A single dose of Gd-PLP-L (20mgPLP/kg/week, i.v.) was found to significantly inhibit tumor growth compared to non-treated mice (P

Original language	English
Pages (from-to)	10-17
Journal	Journal of Controlled Release
Volume	151
Issue number	1
DOIs	https://doi.org/10.1016/j.jconrel.2010.11.031
Publication status	Published - 10 Apr 2011

Keywords

Anti-tumor therapy
Tumor-associated inflammation
Multifunctional liposomes
Magnetic resonance imaging
Monitoring of drug delivery

Access to Document

10.1016/j.jconrel.2010.11.031

Cite this

Kluza, E., Yeo, S. Y., Schmid, S., Van der Schaft, D. W. J., Boekhoven, R. W., Schiffelers, R. M., Storm, G., Strijkers, G. J., & Nicolay, K. (2011). Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. Journal of Controlled Release, 151(1), 10-17. https://doi.org/10.1016/j.jconrel.2010.11.031

@article{08079cd0c68042878f8405e411d270ec,

title = "Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity",

abstract = "Tumor-associated inflammation has been recognized as an important tumor growth propagator and, therefore, represents an attractive target for anti-cancer therapy. In the current study, inspired by recent findings on the anti-tumor activity of liposomal glucocorticoids, we introduce paramagnetic and fluorescent liposomes, encapsulating prednisolone phosphate (PLP), to evaluate the local delivery of liposomal glucocorticoids to the tumor and its importance for the therapeutic response. The new multifunctional liposomes (Gd-PLP-L) (120nm diameter, 5.8mg PLP/60?mol lipid, bioexponential blood-clearance kinetics (T(1/2?)=2.4?0.5h, T(1/2?)=42.0?12.4h), drug leakage of 15%/72h (in vitro)), containing 25mol% Gd-DTPA-lipid and 0.1mol% of rhodamine-lipid, were tested in B16F10 melanoma subcutaneously inoculated in C57BL/6 mice, and compared to the original PLP formulation (PLP-L). A single dose of Gd-PLP-L (20mgPLP/kg/week, i.v.) was found to significantly inhibit tumor growth compared to non-treated mice (P",

keywords = "Anti-tumor therapy, Tumor-associated inflammation, Multifunctional liposomes, Magnetic resonance imaging, Monitoring of drug delivery",

author = "Ewelina Kluza and Yeo, {Sin Yuin} and Sophie Schmid and {Van der Schaft}, {Daisy W. J.} and Boekhoven, {Renate W.} and Schiffelers, {Raymond M.} and Gert Storm and Strijkers, {Gustav J.} and Klaas Nicolay",

year = "2011",

month = apr,

day = "10",

doi = "10.1016/j.jconrel.2010.11.031",

language = "English",

volume = "151",

pages = "10--17",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier / Bunge",

number = "1",

}

Kluza, E, Yeo, SY, Schmid, S, Van der Schaft, DWJ, Boekhoven, RW, Schiffelers, RM, Storm, G, Strijkers, GJ & Nicolay, K 2011, 'Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity', Journal of Controlled Release, vol. 151, no. 1, pp. 10-17. https://doi.org/10.1016/j.jconrel.2010.11.031

TY - JOUR

T1 - Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity

AU - Kluza, Ewelina

AU - Yeo, Sin Yuin

AU - Schmid, Sophie

AU - Van der Schaft, Daisy W. J.

AU - Boekhoven, Renate W.

AU - Schiffelers, Raymond M.

AU - Storm, Gert

AU - Strijkers, Gustav J.

AU - Nicolay, Klaas

PY - 2011/4/10

Y1 - 2011/4/10

N2 - Tumor-associated inflammation has been recognized as an important tumor growth propagator and, therefore, represents an attractive target for anti-cancer therapy. In the current study, inspired by recent findings on the anti-tumor activity of liposomal glucocorticoids, we introduce paramagnetic and fluorescent liposomes, encapsulating prednisolone phosphate (PLP), to evaluate the local delivery of liposomal glucocorticoids to the tumor and its importance for the therapeutic response. The new multifunctional liposomes (Gd-PLP-L) (120nm diameter, 5.8mg PLP/60?mol lipid, bioexponential blood-clearance kinetics (T(1/2?)=2.4?0.5h, T(1/2?)=42.0?12.4h), drug leakage of 15%/72h (in vitro)), containing 25mol% Gd-DTPA-lipid and 0.1mol% of rhodamine-lipid, were tested in B16F10 melanoma subcutaneously inoculated in C57BL/6 mice, and compared to the original PLP formulation (PLP-L). A single dose of Gd-PLP-L (20mgPLP/kg/week, i.v.) was found to significantly inhibit tumor growth compared to non-treated mice (P

AB - Tumor-associated inflammation has been recognized as an important tumor growth propagator and, therefore, represents an attractive target for anti-cancer therapy. In the current study, inspired by recent findings on the anti-tumor activity of liposomal glucocorticoids, we introduce paramagnetic and fluorescent liposomes, encapsulating prednisolone phosphate (PLP), to evaluate the local delivery of liposomal glucocorticoids to the tumor and its importance for the therapeutic response. The new multifunctional liposomes (Gd-PLP-L) (120nm diameter, 5.8mg PLP/60?mol lipid, bioexponential blood-clearance kinetics (T(1/2?)=2.4?0.5h, T(1/2?)=42.0?12.4h), drug leakage of 15%/72h (in vitro)), containing 25mol% Gd-DTPA-lipid and 0.1mol% of rhodamine-lipid, were tested in B16F10 melanoma subcutaneously inoculated in C57BL/6 mice, and compared to the original PLP formulation (PLP-L). A single dose of Gd-PLP-L (20mgPLP/kg/week, i.v.) was found to significantly inhibit tumor growth compared to non-treated mice (P

KW - Anti-tumor therapy

KW - Tumor-associated inflammation

KW - Multifunctional liposomes

KW - Magnetic resonance imaging

KW - Monitoring of drug delivery

U2 - 10.1016/j.jconrel.2010.11.031

DO - 10.1016/j.jconrel.2010.11.031

M3 - Article

C2 - 21130819

SN - 0168-3659

VL - 151

SP - 10

EP - 17

JO - Journal of Controlled Release

JF - Journal of Controlled Release

IS - 1

ER -